143 related articles for article (PubMed ID: 23569317)
1. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.
Warren JL; Harlan LC; Stevens J; Little RF; Abel GA
J Clin Oncol; 2013 Jun; 31(16):1984-9. PubMed ID: 23569317
[TBL] [Abstract][Full Text] [Related]
2. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.
Schriber JR; Hari PN; Ahn KW; Fei M; Costa LJ; Kharfan-Dabaja MA; Angel-Diaz M; Gale RP; Ganguly S; Girnius SK; Hashmi S; Pawarode A; Vesole DH; Wiernik PH; Wirk BM; Marks DI; Nishihori T; Olsson RF; Usmani SZ; Mark TM; Nieto YL; D'Souza A
Cancer; 2017 Aug; 123(16):3141-3149. PubMed ID: 28472539
[TBL] [Abstract][Full Text] [Related]
3. Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer.
Murphy CC; Harlan LC; Warren JL; Geiger AM
J Clin Oncol; 2015 Aug; 33(23):2530-6. PubMed ID: 26150445
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database.
Shah GL; Winn AN; Lin PJ; Klein A; Sprague KA; Smith HP; Buchsbaum R; Cohen JT; Miller KB; Comenzo R; Parsons SK
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1823-9. PubMed ID: 26033281
[TBL] [Abstract][Full Text] [Related]
5. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
6. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.
Olszewski AJ; Dusetzina SB; Trivedi AN; Davidoff AJ
J Clin Oncol; 2018 Oct; 36(28):2879-2886. PubMed ID: 30113885
[TBL] [Abstract][Full Text] [Related]
7. Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non- Hispanic White race/ethnicity in the United States.
Buck T; Hartley-Brown MA; Efebera YA; Milner CP; Zonder JA; Richardson PG; Salinardi T; Rice MS
Haematologica; 2024 Jun; 109(6):1882-1892. PubMed ID: 38031762
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective.
Chen Y; Lairson DR; Chan W; Huo J; Du XL
J Manag Care Spec Pharm; 2017 Aug; 23(8):831-843. PubMed ID: 28737990
[TBL] [Abstract][Full Text] [Related]
9. Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study.
Esteghamat NS; Brunson A; Rosenberg AS; Schonfeld SJ; Valcarcel B; Abrahão R; Cooley JJP; Meyer CL; Auletta JJ; Morton LM; Muffly L; Wun T; Keegan THM
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e119-e129. PubMed ID: 38195324
[TBL] [Abstract][Full Text] [Related]
10. Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.
Gasoyan H; Anwer F; Casacchia NJ; Kovach JD; Valent J; Wang M; Halpern MT; Rothberg MB
JCO Oncol Pract; 2024 May; 20(5):699-707. PubMed ID: 38354331
[TBL] [Abstract][Full Text] [Related]
11. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.
Kehl KL; Hassett MJ; Schrag D
Cancer Med; 2020 Mar; 9(6):2019-2029. PubMed ID: 31989786
[TBL] [Abstract][Full Text] [Related]
12. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.
Costa LJ; Zhang MJ; Zhong X; Dispenzieri A; Lonial S; Krishnan A; Freytes C; Vesole D; Gale RP; Anderson K; Wirk B; Savani BN; Waller EK; Schouten H; Lazarus H; Meehan K; Sharma M; Kamble R; Vij R; Kumar S; Nishihori T; Kindwall-Keller T; Saber W; Hari PN
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1615-24. PubMed ID: 23939198
[TBL] [Abstract][Full Text] [Related]
13. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
[TBL] [Abstract][Full Text] [Related]
14. Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.
Fakhri B; Fiala MA; Tuchman SA; Wildes TM
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):219-224. PubMed ID: 29429818
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics, treatment patterns, and outcomes among African American and White patients with multiple myeloma in the United States.
Saunders A; Slaff S; Subbiah K; Gu T; Ang KK; Quan MA; Rosenberg AS
Leuk Lymphoma; 2024 Jan; 65(1):109-117. PubMed ID: 37917858
[TBL] [Abstract][Full Text] [Related]
16. Trends in overall survival and costs of multiple myeloma, 2000-2014.
Fonseca R; Abouzaid S; Bonafede M; Cai Q; Parikh K; Cosler L; Richardson P
Leukemia; 2017 Sep; 31(9):1915-1921. PubMed ID: 28008176
[TBL] [Abstract][Full Text] [Related]
17. Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma.
Hartley-Brown M; Cole CE; Price P; Andreini M; Mulligan G; Young AQ; Cho HJ
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):32-39. PubMed ID: 37783639
[TBL] [Abstract][Full Text] [Related]
18. Identifying Determinants of Survival Disparities in Multiple Myeloma Patients Using Electronic Health Record Data.
Cui W; Finkelstein J
Stud Health Technol Inform; 2024 Jan; 310():956-960. PubMed ID: 38269950
[TBL] [Abstract][Full Text] [Related]
19. Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program.
Sereda Y; Alarid-Escudero F; Bickell NA; Chang SH; Colditz GA; Hur C; Jalal H; Myers ER; Layne TM; Wang SY; Yeh JM; Trikalinos TA;
J Natl Cancer Inst Monogr; 2023 Nov; 2023(62):219-230. PubMed ID: 37947329
[TBL] [Abstract][Full Text] [Related]
20. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
